]>
IRCT201505091856N5 IRCT 2015-05-22 Vice-chancellor for research, Kermanshah University of Medical Sciences the evaluation of effectiveness of oral silymarin on memory status of patients with dementia the evaluation of effectiveness of oral silymarin on memory status of patients with dementia 2015-05-09 anticipated 100 Complete https://irct.ir/trial/1447 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 2 Condition 1: Dementia in Alzheimer disease. Condition 2: Vascular dementia. Condition 3: Dementia in other diseases classified elsewhere. Intervention 1: Silymarin, 140 mg tablets, 3 times a day (trade name, Livergol, goldaru company), for 12 weeks. Intervention 2: Placebo tablets identical to silymarin tablets in shape and color, 3 times a day, for 12 weeks. Placebo tablets are made in pharmacology faculty of kermanshah university of medical sciences.
public Dr. Daryoush Afshari
Neurology department, Emam Reza hospital, Kermanshah
Kermanshah Iran (Islamic Republic of) +98 83 3427 6326 dafshari@kums.ac.irafshari_d@yahoo.com Kermanshah University of Medical Sciences scientific Dr Daryoush Afshari
Neurology department, Emam Reza hospital, Kermanshah
Kermanshah Iran (Islamic Republic of) +98 83 3427 6326 dafshari@kums.ac.irafshari_d@yahoo.com Kermanshah University of Medical Sciences Iran (Islamic Republic of) inclusion criteria: 1. definite diagnosis of dementia by an experienced neurologist 2. at least one year has past form the time of the diagnosis exclusion criteria: 1. illiterate persons 2. having epilepsy, cardiovascular diseases, metabolic diseases, respiratory diseases, orthopedic problems and renal failure with serum cratinin level more than 2 3. history of previous stroke 4. acute and severe state of any disease including stroke, pulmonary infection, renal disease, metabolic disturbance or trauma leading to hospitalization during the study 5. using other self care programs that are effective on memory state of patents at the same time of study intervention no limit no limit Both F00 F01 F02 Alzheimer disease is a primary degenerative cerebral disease of unknown etiology with characteristic neuropathological and neurochemical features. The disorder is usually insidious in onset and develops slowly but steadily over a period of several years. Vascular dementia is the result of infarction of the brain due to vascular disease, including hypertensive cerebrovascular disease. The infarcts are usually small but cumulative in their effect. Onset is usually in later life. Cases of dementia due, or presumed to be due, to causes other than Alzheimer disease or cerebrovascular disease. Onset may be at any time in life, though rarely in old age. Treatment - Drugs Placebo Silymarin, 140 mg tablets, 3 times a day (trade name, Livergol, goldaru company), for 12 weeks Placebo tablets identical to silymarin tablets in shape and color, 3 times a day, for 12 weeks. Placebo tablets are made in pharmacology faculty of kermanshah university of medical sciences. Memory status of patients. Timepoint: before and 12 weeks after intervention. Method of measurement: mini mental state examination scale. Drug side effects. Timepoint: 12 weeks after intervention. Method of measurement: history and physical examination. Vice-chancellor for research, Kermanshah University of Medical Sciences Approved 2014-11-11 Kermanshah University of Medical Sciences Kermanshah University of Medical Sciences, Shahid Beheshti boulvered, Kermanshah Kermanshah Iran (Islamic Republic of)